California State Teachers Retirement System lowered its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 9.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,128 shares of the specialty pharmaceutical company’s stock after selling 6,600 shares during the quarter. California State Teachers Retirement System owned 0.18% of AMAG Pharmaceuticals worth $1,143,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System boosted its position in AMAG Pharmaceuticals by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 14,300 shares of the specialty pharmaceutical company’s stock worth $263,000 after acquiring an additional 300 shares during the last quarter. Nordea Investment Management AB boosted its position in AMAG Pharmaceuticals by 1.1% during the 2nd quarter. Nordea Investment Management AB now owns 37,200 shares of the specialty pharmaceutical company’s stock worth $684,000 after acquiring an additional 400 shares during the last quarter. Arizona State Retirement System boosted its position in AMAG Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 18,300 shares of the specialty pharmaceutical company’s stock worth $337,000 after acquiring an additional 400 shares during the last quarter. Teachers Advisors LLC boosted its position in AMAG Pharmaceuticals by 0.7% during the 2nd quarter. Teachers Advisors LLC now owns 62,481 shares of the specialty pharmaceutical company’s stock worth $1,150,000 after acquiring an additional 426 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in AMAG Pharmaceuticals by 2.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 18,766 shares of the specialty pharmaceutical company’s stock worth $346,000 after acquiring an additional 486 shares during the last quarter.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, October 4th. Morgan Stanley assumed coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They set an “overweight” rating and a $26.00 price target for the company. Cantor Fitzgerald reaffirmed a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Cowen Inc reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $24.00.

Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at $14.20 on Friday. AMAG Pharmaceuticals, Inc. has a 12 month low of $11.93 and a 12 month high of $36.83. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/california-state-teachers-retirement-system-sells-6600-shares-of-amag-pharmaceuticals-inc-amag/1725050.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.